Instructional on Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma in Clinical Practice

ASCO 2026 ENCOMPASS Experience:
An Immersive Exploration of the Latest in Oncology Care
A Part of the ENCOMPASS Initiative

PROGRAM CHAIR

Joshua Richter, MD
Associate Professor of Medicine
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Director of Myeloma
Blavatnik Family - Chelsea Medical Center at Mount Sinai
New York, NY

PROGRAM OVERVIEW

This CME-accredited micro-learning activity introduces healthcare professionals to an immersive AR Mobile Application designed to enhance patient-centered care in relapsed/refractory multiple myeloma (R/R MM). Through a brief faculty-led demonstration, learners will explore the practical use of AR technology to reinforce clinical concepts, support shared decision-making, and improve communication with patients and colleagues.

TARGET AUDIENCE

The proposed education will be designed to meet the educational needs of hematologists, hematologist/oncologists, oncologists, and APPs (nurse practitioners, oncology nurses) involved in the treatment and management of MM.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Evaluate the clinical data for current and emerging bispecific antibodies as well as how to personalize and sequence therapy for R/R MM.
  • Integrate strategies to identify and manage adverse events associated with bispecific antibodies

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtually live activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.

ACCME INNOVATION PARTNER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

Faculty Member Disclosures
Joshua Richter, MD
Consulting Fee: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Genentech, Abbvie, Regeneron, Forus, Menarini
Speakers Bureau: Kite/Arcellx, UB Therapeutics, Janssen, BMS, Sanofi, Adaptive Biotechnologies, Pfizer

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
  • Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
  • Lauren Scott, MS, Medical Director for Med Learning Group, has nothing to disclose.
  • Aimee Meissner, Accreditation and Outcomes Coordinator, has nothing to disclose.
  • Shannon Mutch MS, RN, OCN, has nothing to disclose.
  • M. Susan Burke, MD, has nothing to disclose.
  • A medical reviewer from CE Peer Review LLC, has nothing to disclose.
  • Melissa Johnson, Program Director for Med Learning Group, has nothing to disclose.
  • Millena Papastavrou, Associate Program Manager for Med Learning Group, has nothing to disclose.
  • Evan Hooper, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

INSTRUCTIONS ON HOW TO DOWNLOAD IAR APP

  • Press the start button and slowly move your device to scan the area around you
  • Once a flat surface has been found, a marker will appear onscreen
  • Move your device to reposition the marker and tap the screen when you are ready to begin
  • Try rotating your device to landscape mode for a wider view

RELEASED DATE: May 30, 2026
EXPIRATION DATE: May 30, 2027

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Pin It on Pinterest

Scroll to Top

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers